Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth

International Journal of Cancer

Volumn 130, Issue 7, 2012, Pages 1521-1531

  Wolff, Dennis W ^a   Xie, Yan ^a   Deng, Caishu ^a   Gatalica, Zoran ^a   Yang, Mingjie ^a   Wang, Bo ^a   Wang, Jincheng ^a,b   Lin, Ming Fong ^c   Abel, Peter W ^a   Tu, Yaping ^a,b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF BIOPHYSICS   (China)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

androgen receptor; DNA methylation; G protein coupled receptors; prostate cancer progression; RGS2

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; RGS2 PROTEIN; SHORT HAIRPIN RNA;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; CPG ISLAND; DOWN REGULATION; EMBRYO; EPIGENETICS; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN METHYLATION; REGULATOR OF G PROTEIN SIGNALING 2 GENE; REPORTER GENE; TRANSACTIVATION; TRANSIENT EXPRESSION; TUMOR GENE;

ANDROGENS; ANIMALS; AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; EPIGENOMICS; EPITHELIAL CELLS; HEK293 CELLS; HUMANS; MALE; MICE; MICE, NUDE; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, G-PROTEIN-COUPLED; RGS PROTEINS; RNA, SMALL INTERFERING;

EID: 84856319563     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26138     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45. (Pubitemid 33741879)
3. Lassi K, Dawson NA,. Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol 2009; 21: 260-5.
4. Heinlein CA, Chang C,. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308. (Pubitemid 38501396)
5. Taplin ME, Balk SP,. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004; 91: 483-90.
6. Edwards J, Krishna NS, Grigor KM, Bartlett JM,. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003; 89: 552-6. (Pubitemid 37026442)
7. Daaka Y,. G proteins in cancer: the prostate cancer paradigm. Sci STKE 2004; 2004: re2.
8. Zhu ML, Kyprianou N,. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008; 15: 841-9.
9. Marinissen MJ, Gutkind JS,. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 2001; 22: 368-76. (Pubitemid 32592476)
10. Kasbohm EA, Guo R, Yowell CW, Bagchi G, Kelly P, Arora P, Casey PJ, Daaka Y,. Androgen receptor activation by G(s) signaling in prostate cancer cells. J Biol Chem 2005; 280: 11583-9. (Pubitemid 40418471)
11. Dai J, Shen R, Sumitomo M, Stahl R, Navarro D, Gershengorn MC, Nanus DM,. Synergistic activation of the androgen receptor by bombesin and low-dose androgen. Clin Cancer Res 2002; 8: 2399-405. (Pubitemid 34753615)
12. Lee LF, Guan J, Qiu Y, Kung HJ,. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 2001; 21: 8385-97. (Pubitemid 33108599)
13. Xie Y, Wolff DW, Lin MF, Tu Y,. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells. Mol Pharmacol 2007; 72: 73-85. (Pubitemid 46998526)
14. Nelson JB,. Endothelin inhibition: novel therapy for prostate cancer. J Urol 2003; 170: S65-S67.
15. Growcott JW,. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs 2009; 20: 83-8.
16. Cao X, Qin J, Xie Y, Khan O, Dowd F, Scofield M, Lin MF, Tu Y,. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene 2006; 25: 3719-34. (Pubitemid 43980493)
17. Ross EM, Wilkie TM,. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem 2000; 69: 795-827.
18. Neubig RR, Siderovski DP,. Regulators of G-protein signalling as new central nervous system drug targets. Nat Rev Drug Discov 2002; 1: 187-97. (Pubitemid 37361422)
19. Wieland T, Mittmann C,. Regulators of G-protein signalling: multifunctional proteins with impact on signalling in the cardiovascular system. Pharmacol Ther 2003; 97: 95-115. (Pubitemid 36136081)
20. Oliveira-Dos-Santos AJ, Matsumoto G, Snow BE, Bai D, Houston FP, Whishaw IQ, Mariathasan S, Sasaki T, Wakeham A, Ohashi PS, Roder JC, Barnes CA, et al. Regulation of T cell activation, anxiety, and male aggression by RGS2. Proc Natl Acad Sci USA 2000; 97: 12272-7.
21. Hurst JH, Hooks SB,. Regulator of G-protein signaling (RGS) proteins in cancer biology. Biochem Pharmacol 2009; 78: 1289-97.
22. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA,. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 2005; 436: 272-6. (Pubitemid 41021279)
23. Schwable J, Choudhary C, Thiede C, Tickenbrock L, Sargin B, Steur C, Rehage M, Rudat A, Brandts C, Berdel WE, Muller-Tidow C, Serve H,. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. Blood 2005; 105: 2107-14. (Pubitemid 40731799)
24. Eszlinger M, Holzapfel HP, Voigt C, Arkenau C, Paschke R,. RGS 2 expression is regulated by TSH and inhibits TSH receptor signaling. Eur J Endocrinol 2004; 151: 383-90. (Pubitemid 39307327)
25. Jiang Z, Wang Z, Xu Y, Wang B, Huang W, Cai S,. Analysis of RGS2 expression and prognostic significance in stage II and III colorectal cancer. Biosci Rep 2010; 30: 383-90.
26. Bird AP,. CpG-rich islands and the function of DNA methylation. Nature 1986; 321: 209-13. (Pubitemid 16016411)
27. Jones PA, Laird PW,. Cancer epigenetics comes of age. Nat Genet 1999; 21: 163-7. (Pubitemid 29070360)
28. Herman JG, Baylin SB,. Promoter-region hypermethylation and gene silencing in human cancer. Curr Top Microbiol Immunol 2000; 249: 35-54. (Pubitemid 30133492)
29. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF,. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 2002; 50: 222-35. (Pubitemid 34184661)
30. Zou MX, Roy AA, Zhao Q, Kirshenbaum LA, Karmazyn M, Chidiac P,. RGS2 is upregulated by and attenuates the hypertrophic effect of alpha1-adrenergic activation in cultured ventricular myocytes. Cell Signal 2006; 18: 1655-63.
31. Qin J, Xie Y, Wang B, Hoshino M, Wolff DW, Zhao J, Scofield MA, Dowd FJ, Lin MF, Tu Y,. Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis. Oncogene 2009; 28: 1853-63.
32. Gatalica Z, Lele SM, Rampy BA, Norris BA,. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma. Cancer 2000; 88: 1378-83. (Pubitemid 30155175)
33. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG,. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64: 1975-86. (Pubitemid 38339443)
34. Karan D, Schmied BM, Dave BJ, Wittel UA, Lin MF, Batra SK,. Decreased androgen-responsive growth of human prostate cancer is associated with increased genetic alterations. Clin Cancer Res 2001; 7: 3472-80. (Pubitemid 33069983)
35. Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK,. Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 2002; 23: 967-75. (Pubitemid 34752952)
36. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT,. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 2003; 54: 249-57. (Pubitemid 36228161)
37. Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW,. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999; 35: 403-9. (Pubitemid 29380004)
38. Chen H, Libertini SJ, George M, Dandekar S, Tepper CG, Al-Bataina B, Kung HJ, Ghosh PM, Mudryj M,. Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocr Relat Cancer 2010; 17: 857-73.
39. Sirotnak FM, She Y, Lee F, Chen J, Scher HI,. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 2002; 8: 3870-6. (Pubitemid 35424782)
40. Plass C, Smiraglia DJ,. Genome-wide analysis of DNA methylation changes in human malignancies. Curr Top Microbiol Immunol 2006; 310: 179-98. (Pubitemid 47400290)
41. Thirunavukkarasu K, Halladay DL, Miles RR, Geringer CD, Onyia JE,. Analysis of regulator of G-protein signaling-2 (RGS-2) expression and function in osteoblastic cells. J Cell Biochem 2002; 85: 837-50. (Pubitemid 34462793)
42. Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, McNeal JE, Ho SM,. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 2004; 164: 2003-12. (Pubitemid 38669349)
43. Perry AS, Foley R, Woodson K, Lawler M,. The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr Relat Cancer 2006; 13: 357-77. (Pubitemid 43886663)
44. Richiardi L, Fiano V, Vizzini L, De ML, Delsedime L, Akre O, Tos AG, Merletti F,. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol 2009; 27: 3161-8.
45. Nelson WG, De Marzo AM, Yegnasubramanian S,. Epigenetic alterations in human prostate cancers. Endocrinology 2009; 150: 3991-4002.
46. Patra SK, Patra A, Zhao H, Dahiya R,. DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog 2002; 33: 163-71. (Pubitemid 34195197)
47. Jaskelioff M, Peterson CL,. Chromatin and transcription: histones continue to make their marks. Nat Cell Biol 2003; 5: 395-9. (Pubitemid 36592261)
48. Ellinger J, Kahl P, von der GJ, Rogenhofer S, Heukamp LC, Gutgemann I, Walter B, Hofstadter F, Buttner R, Muller SC, Bastian PJ, von RA,. Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010; 70: 61-9.
49. Chang SS, Heston WD,. The clinical role of prostate-specific membrane antigen (PSMA). Urol Oncol 2002; 7: 7-12.
50. Ellinger J, Bastian PJ, Jurgan T, Biermann K, Kahl P, Heukamp LC, Wernert N, Muller SC, von RA,. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 2008; 71: 161-7. (Pubitemid 351173282)